Liver-targeted exosome nano-particles capable of enhancing mucus permeability as well as preparation method and application of liver-targeted exosome nano-particles

By using exosome nanoparticles modified with DSPE-PEG-Pep liver-targeting ligand, and utilizing the conformational changes of pH-responsive stretchable cell-penetrating peptides at different pH values, the problems of low oral insulin absorption and low efficiency of traditional carriers are solved, achieving liver-targeted delivery and high bioavailability.

CN118903444APending Publication Date: 2024-11-08CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410904942.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing technologies, the absorption of oral insulin is hindered by the physiological barrier of the gastrointestinal tract, resulting in low bioavailability. Furthermore, subcutaneous injection can easily cause hypoglycemia and local tissue damage. Traditional exosome carriers are inefficient due to steric hindrance and electrostatic interactions.

Method used

Exosomal nanoparticles modified with DSPE-PEG-Pep liver-targeting ligands utilize the conformational changes of the pH-responsive stretchable cell-penetrating peptide Pep-cys at different pH values ​​to cross the gastrointestinal barrier and specifically guide drugs to the liver. The hydrophilic and hydrophobic properties of the DSPE-PEG group improve circulation stability and transmembrane capacity.

Benefits of technology

It improves the bioavailability of insulin, achieves liver-targeted delivery, enhances drug accumulation and therapeutic effect in the liver, avoids interference between carriers, and simplifies the operation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903444A_ABST
    Figure CN118903444A_ABST
Patent Text Reader

Abstract

The invention discloses liver-targeted exosome nanoparticles capable of enhancing mucus permeability as well as a preparation method and application of the liver-targeted exosome nanoparticles. The preparation method comprises the following steps: centrifuging an exosome-containing material for multiple times through an ultra-high-speed refrigerated centrifuge to obtain the exosome, and modifying a liver targeting cell penetrating peptide (Pep for short) onto distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide (DSPE-PEG-MAL) in a Michael addition manner to obtain the liver targeting ligand (DSPE-PEG-Pep). After insulin-loaded nano ions are prepared from the exosome in a self-assembly manner, the insulin-loaded nano ions and a liver-targeted ligand are co-incubated to obtain the liver-targeted exosome nano particles. As a biocompatible carrier, the exosome has advantages in the aspects of medicine cross-mucous layer and cross-intestinal epithelial cell membrane. The Pep amino acid sequence on the liver targeting ligand not only has the liver targeting capability, but also can realize high-efficiency mucus permeability through a folding effect. A plurality of carriers are combined to deliver the medicine, so that the mucous permeability and transmembrane efficiency of the medicine are greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a liver-targeted exosome nanoparticle with enhanced mucus permeability and a preparation method and application thereof, and belongs to the field of polymer materials and pharmaceutical preparations. Background Art

[0002] Diabetes is a chronic disease characterized by high blood sugar. It is a metabolic disorder endocrine disease. Type 2 diabetes accounts for the majority of diabetes patients in my country. Patients with long-term type 2 diabetes often have serious complications (Nutr Metab (Lond), 2017, 14: 60.). At present, the main clinical treatment for diabetes is exogenous insulin injection, but a slight deviation in the subcutaneous injection dose will cause hypoglycemia, and diabetic patients need multiple injections, which will cause pain and local skin tissue necrosis. Oral insulin is a convenient insulin preparation. However, the gastrointestinal tract is the most important site for oral drug absorption, and the complex physiological barriers seriously hinder the absorption of insulin.

[0003] Exosomes are three-dimensional spherical structures composed of phospholipid bilayers, and their main lipid structures are cholesterol, saturated fatty acids and sphingomyelin. Exosomes not only have the structure of lipid rafts, but also have a variety of strictly controlled related proteins and marker proteins on the surface, just like cell membranes. Exosomes can transport molecules such as proteins, nucleic acids and lipids between cells and are often used as natural carriers of signal molecules. Exosomes have the advantages of biocompatibility, circulation stability, biological barrier permeability, low immunogenicity and low toxicity. Their nanosize is between 50-150nm, which can escape the rapid clearance of the mononuclear phagocyte system. Based on the above characteristics, exosomes are often used as carriers of exogenous therapeutic molecules. Milk is a common food in daily life, and the exosomal properties and immunogenicity of milk extracted from milk can also be ignored. In 2016, Gupta et al. systematically proved for the first time that milk can be used as a source of exosomes, and its in vivo stability and biocompatibility after oral administration are excellent. Moreover, milk exosomes are amphiphilic substances, which are drug carriers with both hydrophilic and lipophilic properties. In theory, they have advantages in crossing the mucus layer and intestinal mucosal cells.

[0004] When modifying drug carriers with different surface ligands, factors such as steric hindrance and electrostatic interactions often hinder the binding of carriers to receptors, resulting in the efficacy of carrier nanoparticles and the efficiency of drug delivery in vivo being affected. A common strategy is to use the enzyme response principle to connect multiple ligands to nanoparticles, and use specific enzymes to cleave the linker to expose another ligand and play a role. However, such an operation will introduce unwanted ligand groups. Summary of the invention

[0005] Objectives of the invention: The first objective of the present invention is to provide a drug carrier for liver-targeted exosome delivery; the second objective of the present invention is to provide a method for preparing a drug carrier for liver-targeted exosome delivery; the third objective of the present invention is to provide a liver-targeted exosome nanoparticle with enhanced mucus permeability, the fourth objective of the present invention is to provide a method for preparing liver-targeted exosome nanoparticle with enhanced mucus permeability, and the fifth objective of the present invention is to provide the use of the drug carrier for liver-targeted exosome delivery or the liver-targeted exosome nanoparticle with enhanced mucus permeability in the preparation of a drug for treating diabetes.

[0006] Technical solution: The drug carrier for liver-targeted exosome delivery described in the present invention is a liver-targeted ligand DSPE-PEG-Pep, and its structural formula is as follows:

[0007]

[0008] Where n represents the average number of polyethylene glycols.

[0009] Preferably, the PEG in the liver targeting ligand DSPE-PEG-Pep is PEG 2000 (PEG 2k ), PEG 3400 or PEG 5000 More preferably, PEG is PEG 2000 .

[0010] On the other hand, the present invention provides a method for preparing the above-mentioned drug carrier for liver-targeted exosome delivery, characterized in that the method is:

[0011]

[0012] Maleimide-polyethylene glycol-distearoylphosphatidylethanolamine (DSPE-PEG-MAL) and liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys were modified by Michael addition to obtain liver-targeted ligand DSPE-PEG-Pep. 6 G 5 (HE) 10 Pep (Pep-cys for short) mimics the spike protein on the surface of the virus and undergoes conformational changes depending on the pH value. Under normal circumstances, Pep presents a stretched conformation, and in the intestinal environment, the surface will extend, mediating the passage through the intestinal barrier. After entering the systemic circulation, Pep will fold, exposing its liver-targeting functional fragment on the surface, thereby achieving guided drug delivery to the liver.

[0013] Maleimide-polyethylene glycol has both hydrophilicity and hydrophobicity. The delivery material prepared with it can significantly improve the circulation time and stably encapsulate drugs, and can be well modified to carry target ligands or targeted substances. Choosing the DSPE-PEG group as the main body can make it embedded with the ligand fragment into the exosome drug delivery system. Its structure similar to the phospholipid bilayer has advantages in being captured by macrophages and crossing the membrane.

[0014] The above technical solution uses the above material technologies in combination to prepare an oral drug carrier that has efficient intestinal transmembrane transport capability, the ability to overcome the gastrointestinal barrier, liver targeting capability and excellent biocompatibility, thereby effectively improving the bioavailability of hypoglycemic drugs.

[0015] Furthermore, the preparation method of the liver-targeted drug carrier is specifically as follows: under a nitrogen protection environment, DSPE-PEG-MAL and the liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys are dissolved in an organic solvent, a catalyst is added, and the reaction is stirred at room temperature. After the reaction is completed, the product is collected, which is the liver-targeted ligand DSPE-PEG-Pep.

[0016] More specifically, the preparation method of the liver-targeted drug carrier is as follows: under a nitrogen protection environment, a small amount of organic solvent is used to dissolve DSPE-PEG-MAL and a liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys, a few drops of catalyst are added, and the mixture is stirred at room temperature for reaction. After the reaction is completed, the mixture is precipitated with ice ether and the lower precipitate is removed by centrifugation, washed and dried to obtain the liver-targeted ligand DSPE-PEG-Pep;

[0017] Furthermore, the organic solvent is DMF, methanol or chloroform.

[0018] Furthermore, the catalyst is triethylamine.

[0019] Furthermore, the liver-targeted ligand DSPE-PEG-Pep is connected to the thiol group of the liver-targeted polypeptide sequence Pep-cys through the double bond of DSPE-PEG-MAL through a Michael addition reaction, and the molar ratio of DSPE-PEG-MAL to the liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys is 1-1.5:1.

[0020] Furthermore, during the glacial ether precipitation, the volume ratio of the reaction solution to the glacial ether is 1:4-10.

[0021] On the other hand, the present invention provides a method for extracting exosomes, which comprises first removing macromolecular substances and precipitates in the material, then taking the supernatant and centrifuging to remove vesicles and small molecular substances, and finally using a high-speed centrifuge tube and an ultra-high-speed refrigerated centrifuge to precipitate the exosomes.

[0022] Specifically, the extraction of exosomes is to centrifuge the exosome material multiple times using low-temperature high-speed centrifugation to remove macromolecular substances and precipitates in the material. Then, use an ultra-high-speed refrigerated centrifuge to centrifuge to remove small molecules such as vesicles. Finally, transfer the supernatant to a high-speed centrifuge tube, centrifuge again using an ultra-high-speed refrigerated centrifuge, and wash the precipitate with PBS to finally obtain an exosome solution.

[0023] Furthermore, in the extraction of exosomes, the high-speed centrifuge was set at 10000-13000 g for 30-60 min.

[0024] Furthermore, in the extraction of exosomes, the ultra-high speed refrigerated centrifuge was set at 80000-110000 g for 30-60 min when removing vesicles and other substances; and the program was set at 130000-200000 g for 30-60 min when precipitating exosomes.

[0025] Preferably, the source of the exosomes includes any one of milk exosomes, ginger exosomes and cellular exosomes.

[0026] On the other hand, the present invention provides a liver-targeted exosome nanoparticle, which comprises the above-mentioned liver-targeted ligand DSPE-PEG-Pep, exosomes and insulin; wherein the exosomes are loaded with insulin in a self-assembled manner, and then co-incubated with the liver-targeted ligand to obtain the liver-targeted exosome nanoparticle.

[0027] The preparation of drug-loaded nanoparticles by loading insulin in a self-assembly manner is obtained by mixing the extracted exosomes with insulin and ultrasonically treating them with a cell ultrasonic disruptor.

[0028] Among them, liver-targeted pH-triggered stretchable cell-penetrating peptide Pep R 6 G 5 (HE) 10 (Pep-cys for short) can be replaced by the cationic peptide poly-L-arginine (pArg for short).

[0029] In another aspect, the present invention provides a method for preparing liver-targeted exosome nanoparticles, comprising the following steps:

[0030] The insulin solution was mixed with the exosome solution, and then ultrasonically treated. The drug-loaded nanoparticles obtained by fully mixing and assembling were recorded as mEXO@ins.

[0031] The DSPE-PEG-Pep solution was mixed with mEXO@ins for co-incubation. After the incubation, the unconnected ligand structure was removed by centrifugation, and the obtained liver-targeted drug-loaded nanoparticles were DSPE-PEG-Pep-mEXO@ins.

[0032] Specifically, the preparation method of liver-targeted exosome nanoparticles includes the following steps: dissolving bovine insulin in advance with a hydrochloric acid solution of pH 2.0 as a solvent to prepare an insulin solution with a concentration of 20 mg / mL. When preparing the drug-loaded nanoparticle solution mEXO@ins, the insulin solution is mixed with the milk exosome solution, and after mixing, it is ultrasonically treated with a cell ultrasonic disruptor. The drug-loaded nanoparticles obtained by fully mixing and assembling are recorded as mEXO@ins. DSPE-PEG-Pep is dissolved in a PBS solution to prepare a ligand solution with a concentration of 10 mg / mL. The DSPE-PEG-Pep solution is mixed with mEXO@ins and incubated in a shaker incubator for a period of time. After the incubation is completed, the unconnected ligand structure is removed by centrifugation to obtain liver-targeted exosome drug-loaded nanoparticles.

[0033] Furthermore, in the preparation of liver-targeted exosome nanoparticles, the ultrasonic treatment procedure is 75-120W, 2-5min.

[0034] Furthermore, in the preparation of liver-targeted exosome nanoparticles, the DSPE-PEG-Pep solution was mixed with mEXO@ins in a volume ratio of 1:5-10.

[0035] Furthermore, in the preparation of liver-targeted exosome nanoparticles, when removing unattached ligands, the centrifugation condition is 2000-3500 r·min -1 , 3-5min.

[0036] Specifically, the method for preparing liver-targeted exosome nanoparticles comprises the following steps:

[0037] (1) Preparation of liver-targeting ligands:

[0038] DSPE-PEG-Mal and liver-targeted pH-triggered stretchable cell-penetrating peptide (Pep-cys) solids were accurately weighed in a ratio of 1:1-1.5, dissolved in DMF, and three drops of triethylamine were added to catalyze the reaction. The whole reaction process was carried out under N 2 After the reaction is completed, the viscous liquid obtained by the reaction is added dropwise into icy ether (the volume is 4-6 times of the reaction liquid) for precipitation. The icy ether containing flocculent precipitation is placed in a -20°C refrigerator for refrigeration. After the product is completely precipitated, the product is centrifuged. The precipitated part is taken and vacuum dried.

[0039] (2) Extraction of milk exosomes:

[0040] Add milk to a 50mL centrifuge tube, balance it, centrifuge it twice at 12000g or 13000g for 30-40min, discard the precipitate to remove somatic cells and fat. Take the supernatant and put it in a new 50mL centrifuge tube, mix it with supernatant: EDTA (300-600mmol / L) at a volume ratio of 3-4:1, and let it stand on ice to precipitate milk casein.

[0041] After balancing again, centrifuge at 80000-100000g for 60 minutes to remove fat globules, precipitated proteins and larger vesicles. Take the supernatant to a high-speed centrifuge tube, use an ultra-high-speed refrigerated centrifuge to centrifuge at 130000-150000g for 60 minutes, and discard the supernatant. Wash and resuspend the precipitate three times with phosphate buffered saline (PBS solution), and finally dissolve the precipitate with PBS solution. The resulting solution is the exosome solution.

[0042] (3) Preparation of ligand-modified drug-loaded nanoparticles:

[0043] In advance, bovine insulin was dissolved in a hydrochloric acid solution with a pH of 2.0 as a solvent to prepare an insulin solution with a concentration of 20 mg / mL. When preparing drug-loaded nanoparticles, the insulin solution was added to the milk exosome solution prepared in the above step to prepare nanoparticles with an insulin loading of 30 wt%. After mixing, the mixture was ultrasonically treated for 3 minutes at 75-100 W using a cell ultrasonic disruptor to fully mix and assemble. The obtained drug-loaded nanoparticles were recorded as mEXO@ins.

[0044] The DSPE-PEG-PEP prepared in step (1) was dissolved in a PBS solution to prepare a liver-targeted ligand solution. The DSPE-PEG-PEP solution was mixed with the mEXO@ins prepared by the above operation at a volume ratio of 1:10-15, and incubated in a shaking incubator at 37°C and 80 r / min. After the incubation, the solution was centrifuged at 2000-3000 r / min for 5 min to remove the unattached ligand DSPE-PEG-PEP, and the drug delivery system was DSPE-PEG-PEP-mEXO@ins.

[0045] On the other hand, the present invention provides a use of the above-mentioned drug carrier for liver-targeted exosome delivery in the preparation of a drug for treating diabetes.

[0046] On the other hand, the present invention provides an application of the above-mentioned liver-targeted exosome nanoparticles in the preparation of a drug for treating diabetes. Further, when used, an exosome solution is prepared, and the hypoglycemic drug insulin is added to prepare exosome drug-loaded nanoparticles in a self-assembly manner. A liver-targeted ligand solution is prepared, mixed and incubated with the exosome drug-loaded nanoparticles to prepare liver-targeted exosome drug-loaded nanoparticles. The nanoparticles are used orally.

[0047] The liver-targeted exosome nanoparticles of the present invention are first modified by Michael addition of DSPE-PEG-MAL and a liver-targeted polypeptide sequence (Pep) to obtain a liver-targeted ligand (DSPE-PEG-Pep), and the exosome-containing raw material is centrifuged multiple times using an ultra-high-speed refrigerated centrifuge to obtain the exosomes. After that, the exosomes are loaded with insulin in a self-assembled manner, and then co-incubated with the liver-targeted ligand to obtain the liver-targeted exosome nanoparticles.

[0048] The present invention synthesizes and uses for the first time an exosome drug delivery system modified with a ligand group having a liver-targeting function. The Pep group not only provides a liver-targeting effect, but also, as a pH-responsive stretchable cell-penetrating peptide, can adjust the conformation of the ligand to give it a unique surface feature similar to that of a virus, thereby giving full play to the multiple functions of multiple ligands and avoiding mutual interference between them. As a common endogenous natural ligand, milk exosomes have excellent biocompatibility and effectively reduce the toxic and side effects of drugs. Their small nanosize can escape rapid clearance by phagocytes. The introduction of the DSPE-PEG group enables the drug to have both hydrophilic and lipophilic effects, and makes the carrier electrically neutral, which has great advantages in maintaining the stability of the carrier system, crossing the mucus layer and crossing the membrane. The combined use of multiple carriers can achieve long-term drug circulation, which has potential application prospects in the treatment of diabetes.

[0049] Beneficial effects: Compared with the existing technology, it has the following advantages:

[0050] (1) The exosome nanoparticles designed in the present invention use milk exosomes as the main carrier. As an important oral drug carrier, exosomes have the advantages of excellent biocompatibility, long-term circulation effect and intrinsic ability to encapsulate biomacromolecules. Milk-derived exosomes have the advantages of pH self-adaptation during gastrointestinal transportation, intestinal mucus penetration, active uptake of multiple cell membrane targets, and activation of nutrient assimilation-related pathways. They have great advantages in maintaining the stability of oral carriers, intestinal mucus layer permeability, and penetrating cell membranes.

[0051] (2) Liver-targeted pH-triggered stretchable cell-penetrating peptide (Pep-cys) undergoes conformational changes depending on the pH value, which helps to avoid mutual interference between different groups. At the pH of the digestive tract, Pep adopts a stretched conformation to mediate effective passage through the intestinal barrier. After the drug enters the systemic circulation, Pep folds at physiological pH, and the DSPE-PEG group takes effect, thereby specifically directing the drug to the liver. The application of liver-targeted technology can increase the accumulation of drugs in the liver, exert a precise therapeutic effect, improve the bioavailability of oral administration, and achieve a longer-acting circulation of drugs. Insulin acts directly on the insulin receptors on the liver, promotes the liver's uptake of glucose and converts it into glycogen, and effectively improves the bioavailability of insulin.

[0052] (3) The present invention utilizes the Michael addition reaction of carbon-carbon double bonds and thiol groups to modify target molecules on macromolecular compounds, which is easy to operate and requires simple conditions.

[0053] (4) The present invention utilizes centrifugation to obtain exosomes, and the exosomes are derived from milk exosomes. The method of obtaining the exosomes is simple, the oral toxicity of the material is low, and the biocompatibility is good. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 DSPE-PEG in Example 1 2k -H NMR spectrum of Pep;

[0055] Figure 2 Figure 3 is the particle size and potential diagram of the nanoparticles in Example 3, wherein Figure (A) is the particle size information of the unloaded nanoparticles mEXO and DPP-mEXO, Figure (B) is the particle size information of the drug-loaded nanoparticles mEXO@ins and DPP-mEXO@ins, Figure (C) is the potential information of the unloaded nanoparticles mEXO and DPP-mEXO, and Figure (D) is the potential information of the drug-loaded nanoparticles mEXO@ins and DPP-mEXO@ins;

[0056] Figure 3 is a Coomassie brilliant blue staining image of the nanoparticles in Example 4;

[0057] Figure 4 It is the Western blot of mEXO and DPP-mEXO in Example 4;

[0058] Figure 5 This is a graph showing the particle size change of the drug-loaded nanoparticles in Example 5 during low-temperature storage;

[0059] Figure 6 This is the simulated in vivo release profile of the drug-loaded nanoparticles in Example 5;

[0060] Figure 7 Schematic diagram of cell survival rate in the cytotoxicity test in Example 5, wherein (A) is a Caco-2 cytotoxicity test; (B) is a HT-29 cytotoxicity test;

[0061] Figure 8 Schematic diagram of mucus penetration of drug-loaded nanoparticles in Example 5;

[0062] Fig. 9 Schematic diagram of the in vivo glucose-lowering effect of the drug-loaded nanoparticles in Example 5. DETAILED DESCRIPTION

[0063] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0064] The embodiment of the present invention provides a drug carrier for liver-targeted exosome delivery, wherein the drug carrier is a liver-targeted ligand DSPE-PEG-Pep, and its structural formula is as follows:

[0065]

[0066] Where n represents the average number of oxyethylene groups. The following examples are described in detail with the PEG in DSPE-PEG-Pep being PEG2000. 2k -Pep's trade name is distearoylphosphatidylethanolamine-polyethylene glycol-maleimide, which was purchased from Xi'an Ruixi Biotechnology Co., Ltd. PEP-cys was purchased from Suzhou Qiangyao Biotechnology Co., Ltd. PEP-cys was synthesized by Fmoc solid phase synthesis method using Fmoc-Gly-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tbu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(pbf)-OH, Fmoc-Pro-OH, Fmoc-Val-OH, Fmoc-Ser(tbu)-OH, Fmoc-Ala-OH, and Fmoc-Cys(Trt)-OH as protected amino acid raw materials. The specific operation is to connect the amino acids from left to right in sequence on the swollen resin, repeat the steps of connecting amino acids, eluting protective groups, and detecting until all amino acids are successfully connected, purify and wash the polypeptide, and freeze-dry the sample to obtain the PEP-cys product.

[0067] Example 1

[0068] DSPE-PEG 2k -Pep synthesis, synthesis route and process are as follows:

[0069]

[0070] Accurately weigh 64 mg DSPE-PEG 2k -Mal (0.022 mmol) and 40 mg PEP-cys (0.022 mmol) were dissolved in 8 mL DMF (N,N-dimethylformamide), and 3 drops of triethylamine were added as a catalyst. The reaction was stirred at room temperature for 24 h. 2 After the reaction, the viscous liquid obtained by the reaction was added dropwise into 40 mL of icy ether (the volume was 4-10 times that of the reaction solution) for precipitation. The icy ether containing the flocculent precipitate was placed in a -20°C refrigerator for 24 hours. After the product was completely precipitated, the product was centrifuged (8000 rpm, 5 min). The precipitate was taken and vacuum dried for 8 hours. 94.10 mg of the white precipitate product was weighed, DSPE-PEG 2k-Pep yield is about 90.47%. Its H NMR spectrum is as follows Figure 1 shown.

[0071] In the above embodiment, the amount of PEP-cys added was replaced with 0.033 mmol, and the other conditions remained unchanged, and DSPE-PEG was also obtained. 2k -Pep.

[0072] Example 2

[0073] Extraction of milk exosomes, the extraction process is as follows:

[0074] The milk purchased in the experiment was Yili boxed pure milk. The extraction method was high-speed centrifugation, and the instrument used was a low-temperature high-speed centrifuge. The milk was added to a 50mL centrifuge tube, and after balancing, it was centrifuged twice at 13000g and 30min, and the precipitate was discarded to remove somatic cells and fat. The supernatant was taken to a new 50mL centrifuge tube, and the supernatant: EDTA (pH 7.0, 500mmol / L) was mixed at a volume ratio of 3:1, and placed on ice for 15min to precipitate milk casein.

[0075] After rebalancing, centrifuge at 100000g for 60 min to remove fat globules, precipitated proteins and larger vesicles. Take the supernatant to a high-speed centrifuge tube and centrifuge at 135000g for 60 min using an ultra-high-speed refrigerated centrifuge, and discard the supernatant. Wash and resuspend the precipitate three times with phosphate buffered saline (PBS solution), and finally dissolve the precipitate with PBS solution. The resulting solution is the exosome solution (30 mg / mL).

[0076] Example 3

[0077] (1) Preparation of mEXO@ins nanoparticles

[0078] In advance, bovine insulin was dissolved in a hydrochloric acid solution with a pH of 2.0 as a solvent to prepare an insulin solution with a concentration of 20 mg / mL. When preparing drug-loaded nanoparticles, 53.5 μL of insulin solution was added to 1 mL of the milk exosome solution prepared in Example 2 to prepare nanoparticles with an insulin loading of 30 wt%. After mixing, the mixture was ultrasonically treated for 3 minutes using a cell ultrasonic disruptor at 100 W, 2s / 2s to fully mix and assemble. The resulting nanoparticles were recorded as mEXO@ins. At the same time, 1 mL of milk exosomes was mixed with 53.5 μL of PBS to prepare mEXO, and the preparation operation was the same as above.

[0079] (2) Preparation of DPP-mEXO@ins nanoparticles

[0080] Take the DSPE-PEG in Example 1 2k1 mg of -PEP was dissolved in 1 mL of PBS solution, 200 μL of ligand solution (10 mg / mL) was mixed with 1 mL of mEXO@ins in Example 3 (1), and incubated in a shaker incubator at 37°C and 80 rpm for 24 h. After the incubation, the mixture was centrifuged at 2000 rpm for 5 min to remove the unattached DSPE-PEG. 2k -PEP, the resulting drug delivery system is DSPE-PEG 2k -PEP-mEXO@ins, denoted as DPP-mEXO@ins. At the same time, 200 μL DSPE-PEG 2k -PEP solution was mixed with 1 ml of mEXO prepared in Example 3(1) to prepare DPP-mEXO, and the preparation procedure was the same as above.

[0081] (3) Detection of empty / drug-loaded nanoparticles

[0082] The nanoparticles in the drug-loaded exosome solution prepared in this example were subjected to particle size analysis and potential analysis, and electron microscope pictures were taken to observe the morphology of the nanoparticles. Before taking electron microscope pictures, the mEXO@ins, mEXO, DPP-mEXO@ins, and DPP-mEXO nanoparticles need to be negatively stained with 2% phosphotungstic acid. Take 20 μL of sample, add it dropwise to the copper mesh, and let it stand for 3 minutes to allow the nanoparticles to precipitate. Then aspirate the droplet, add 20 μL of 2% phosphotungstic acid, and stain for 3 minutes. After staining, aspirate the dye, place it under an incandescent lamp and bake it for 1 minute. After staining, use a projection electron microscope at 100 kV for morphological observation. The observation results are as follows Figure 2 shown.

[0083] Figure 2 The particle size, potential and electron microscope image of the nanoparticles mEXO, mEXO@ins, DPP-mEXO and DPP-mEXO@ins in Example 3 are shown in FIG. Figure 2 It can be seen that the average particle size is about 100 nm, the PDI is about 0.2, and the nanoparticles are electrically neutral or slightly electrically positive.

[0084] (4) Verification of stable modification of liver-targeting ligands

[0085] Take 1 mL of DPP-mEXO prepared in Example (2) (containing about 32 mg of DPP-mEXO), add 20 μL of 5-aminofluorescein at a concentration of 20 mg / mL, and incubate at 37°C for 4 h. The incubated nanoparticle solution is transferred to a centrifugal filter device with a molecular weight cutoff of 12,000 and centrifuged at 8,000 r for 10 min to remove unattached DSPE-PEG. 2k -PEP ligand. The lower layer solution after centrifugation is the unconnected DSPE-PEG 2k-PEP ligand, take 200 μL of the lower layer solution into a black 96-well plate and measure the fluorescence absorption at 488 nm.

[0086] The present invention adopts an indirect method, by measuring the fluorescence absorption of the free ligand containing 5-aminofluorescein, comparing it with the standard curve, and further calculating the concentration of the unattached ligand, thereby calculating the ligand grafting rate. The calculation formulas are as follows:

[0087] Fluorescence absorption standard curve: y = 174609882x + 152146622

[0088]

[0089] Among them, m 总 is the mass of DPP-mEXO input (mg), m 游 is the mass of free DPP-mEXO (mg).

[0090] The DPP-mEXO nanoparticles prepared in this example were characterized and analyzed, and the calculation results showed that the free DSPE-PEG 2k -PEP ligand concentration was 15.05 mg / mL, so DSPE-PEG 2k -PEP ligand grafting rate is about 52.96%.

[0091] In the above embodiment, in the preparation of DPP-mEXO@ins nanoparticles, 100 μL of ligand solution (10 mg / mL) was taken and the centrifugation conditions were changed to: 3500 r·min -1 5min, and other conditions remain unchanged, DPP-mEXO@ins nanoparticles can also be prepared.

[0092] Example 4

[0093] (1) Detection of Nanoparticles Prepared from Extracted Milk Exosomes and Nanoparticles Modified with Targeting Ligands

[0094] The components were detected by Western Blot (WB). The samples were mEXO, mEXO@ins, DPP-mEXO and DPP-mEXO@ins. The detection process was as follows:

[0095] (1) SDS-PAGE: mEXO, mEXO@ins, DPP-mEXO, and DPP-mEXO@ins nanoparticle solutions were mixed with protein loading buffer at a ratio of 4:1, heated at 95°C for 10 min, and then stored in a -20°C refrigerator. When used, 15 μL of the treated sample was loaded onto a precast gel, first electrophoresed at 80 V for 30 min in a concentrated gel, and then electrophoresed at 110 V for 80 min in a separation gel to completely separate proteins of different molecular weights in the sample.

[0096] (2) Staining: After electrophoresis, take the gel and rinse it three times with pure water to remove impurities. Add 20 mL of Coomassie blue protein gel staining solution to cover the gel and stain it overnight at room temperature on a shaker.

[0097] (3) Rinse: After staining, discard the staining solution and rinse the gel membrane with high-purity water for 10 minutes each time, for three times.

[0098] (4) Color development and imaging: Prepare the color development solution according to the instructions of the color development kit used in the laboratory. When using, add 2 mL of the color development solution to the gel membrane for color development, and use a gel imager for imaging observation.

[0099] Test results such as Figure 3 shown.

[0100] Figure 3 This is the Coomassie bright blueprint of the nanoparticles in Example 4, including Marker, mEXO, mEXO@ins, DPP-mEXO and DPP-mEXO@ins from left to right. The protein bands of the extracted mEXO are consistent with those of the sample, and the protein bands of the mEXO connected with the DSPE-PEG-PEP ligand and the single mEXO are consistent, indicating that the milk exosomes of the fusion material will not cause the disappearance of membrane proteins.

[0101] (2) Detection of Nanoparticles Linked to Liver-Targeting Ligands

[0102] Validation of DSPE-PEG by Western Blotting 2k -PEP ligand was successfully connected, and the samples detected by Western blotting were mEXO and DPP-mEXO. The operation is as follows.

[0103] (1) SDS-PAGE: The exosome solution was mixed with the protein loading buffer at a ratio of 4:1, heated at 95°C for 10 min, and then stored in a -20°C refrigerator. When used, 15 μL of the treated sample was loaded onto a precast gel, first electrophoresed at 80 V for 30 min in a concentrated gel, and then electrophoresed at 110 V for 80 min in a separation gel to completely separate proteins of different molecular weights in the sample.

[0104] (2) Rinsing: Cut the filter paper and PVDF membrane in advance, activate the PVDF membrane in anhydrous ethanol until no water droplets are attached, and then soak it in transfer buffer together with the filter paper. Use a sponge and three layers of filter paper to fix the PVDF membrane and protein glue in the middle, and transfer the membrane at 85V in an ice bath for 145 minutes.

[0105] (3) Blocking: After the transfer, the PVDF membrane was removed and cut into appropriate sizes and immersed in a mixed solution of TBS-T and milk powder. The membrane was blocked in a shaking incubator at 37°C and 80 rpm for 30 min to remove adsorbed nonspecific proteins.

[0106] (4) Incubation with antibodies: Based on the properties of milk exosomes, we selected rabbit anti-CD63 antibody (primary antibody) and HRP-coupled goat anti-rabbit IgG antibody (secondary antibody) to detect the properties of the extracted exosomes. The two antibodies were diluted according to the instructions. The PVDF membrane was first infiltrated with rabbit anti-CD63 antibody and incubated overnight at 4°C. After incubation, the PVDF membrane was washed three times with TBS-T solution, each for ten minutes. The PVDF membrane was then infiltrated with HRP-coupled goat anti-rabbit IgG antibody and incubated overnight at 4°C. After incubation, the membrane was also washed with TBS-T buffer.

[0107] (5) Color development and imaging: Prepare the color development solution according to the instructions of the color development kit used in the laboratory. When using, add 2 mL of the color development solution to the PVDF membrane for color development, and use a gel imager for imaging observation.

[0108] Test results such as Figure 4 As shown, the band positions of mEXO and DPP-mEXO are consistent, verifying that both prepared nanoparticles have characteristic proteins CD36 and CD81, and the fusion material still contains the characteristics of milk exosomes.

[0109] Example 5

[0110] (1) Encapsulation efficiency and drug loading of drug-loaded nanoparticles

[0111] The mass encapsulation efficiency (LE) and drug loading (LC) are usually used to indicate the drug loading capacity of nanoparticles. The present invention adopts an indirect method, using the BCA method to measure the content of free insulin not encapsulated in the nanoparticles, and further calculates the drug loading and encapsulation efficiency by the mass of the measured free insulin. The drug loading is the percentage of the amount of drug encapsulated in the nanoparticles and the total mass (the amount of the carrier and the encapsulated drug), and the mass encapsulation efficiency refers to the mass percentage of the amount of drug encapsulated in the nanoparticles and the dosage, and the calculation formulas are as follows:

[0112]

[0113] Among them, m 总 is the mass of insulin injected (mg), m 游 is the mass of free insulin (mg); m 药 is the mass of insulin encapsulated in the nanoparticles (mg), m 载体 is the mass of the final prepared nanoparticles (mg).

[0114] The milk exosome solution nanoparticles prepared in this example were characterized and analyzed, and the results are shown in Table 1. When the theoretical drug loading (i.e., insulin mass / finally prepared nanoparticle mass) was finally selected as 30wt%, the encapsulation rate of insulin by milk exosomes could reach more than 80%.

[0115] Table 1 Characterization of insulin-loaded nanoparticles

[0116]

[0117] (2) Particle size change of drug-loaded nanoparticles during low-temperature storage

[0118] The drug delivery system constructed in this project is mainly based on milk exosomes, which are biomembrane materials and are not suitable for long-term storage at 4°C. In order to explore the short-term storage conditions of DPP-mEXO@ins, the drug delivery system prepared in steps (1) and (2) of Example 3 was frozen in a -20°C refrigerator for 0-30 days. After thawing, the particle size change was detected by a nanoparticle size detector. The experiment analyzed the particle size changes of mEXO, DPP-mEXO, mEXO@ins, and DPP-mEXO@ins in parallel.

[0119] The results of particle size changes of drug-loaded nanoparticles under low-temperature storage are shown in the attached Figure 5 . Figure 5 The particle size change diagram of drug-loaded nanoparticles under low-temperature storage is shown in Figure 2. Figure 5 It can be seen that the particle size of DPP-mEXO@ins did not change significantly within 30 days, and its stability was better than that of other nanosystems, indicating that the drug delivery system DPP-mEXO@ins has good low-temperature storage stability.

[0120] (3) Simulated in vivo release experiment of drug-loaded nanoparticles

[0121] 1 mL of each mEXO@ins and DPP-mEXO@ins solution with an insulin loading of 30 wt% prepared in steps (1) and (2) of Example 3 was placed in a dialysis bag (12 kDa). The sample was placed in a 50 mL centrifuge tube and 3 mL of pH 1.2 PBS buffer solution was added to simulate the pH environment of the stomach. After 2 hours, the dialysis bag was removed and the residual solution on the outside of the bag was wiped dry. The solution in the 50 mL centrifuge tube was replaced with a pH 6.8 PBS buffer solution to simulate the intestinal pH environment. The above operation was repeated at the 6th hour and replaced with a pH 7.4 PBS buffer solution to simulate the blood pH environment. The 50 mL centrifuge tube containing the mEXO@ins and DPP-mEXO@ins samples was placed in a 37°C, 80 r / min incubator, and 50 μL was taken in a 96-well plate at 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours. Each sample was measured in parallel three times. (After each sample is taken, 150 μL of buffer solution of the corresponding pH should be added to ensure that the volume of the buffer solution does not change.)

[0122] After sampling, add 150 μL of Coomassie Brilliant Blue reagent to the sample in the 96-well plate, select the measurement wavelength as 562 nm, measure the absorbance using an enzyme reader in ABS mode, and draw a standard curve of absorbance and insulin concentration to determine the insulin concentration. The cumulative release percentage of insulin at different times is calculated using the following formula:

[0123]

[0124] Where V is the volume of 100 mM phosphate buffer, mL;

[0125] C——insulin concentration in buffer, mg / mL;

[0126] W——the mass of the final prepared drug-loaded exosome solution, mg;

[0127] LC—drug loading of drug-loaded nanoparticles, %.

[0128] The simulated in vivo release results of drug-loaded nanoparticles are shown in Figure 6 . Figure 6 To simulate the in vivo release profile of drug-loaded nanoparticles, Figure 6 It can be seen that in the buffer solution of pH 1.2, insulin is released slowly, showing a delayed effect, while in the buffer solution of pH 6.8, the insulin release rate is accelerated and the cumulative release amount is also increased.

[0129] (4) Cytotoxicity test of drug-loaded nanoparticles (MTT)

[0130] mEXO@ins and DPP-mEXO@ins solutions were prepared according to the methods in steps (1) and (2) of Example 3, and 50 μL of each solution was used for human cloned colon adenocarcinoma (Caco-2) and human colon adenocarcinoma (HT-29) cytotoxicity (MTT) experiments. According to the experimental cell types and the types of nanoparticles added, the cells were divided into two groups: Group A was recorded as mEXO (Caco-2) and DPP-mEXO (Caco-2); Group B was recorded as mEXO (HT-29) and DPP-mEXO (HT-29). The results are shown in Table 1. Figure 7 . Figure 7 Schematic diagram of cell survival rate in Caco-2 and HT-29 cytotoxicity assays. Figure 7 It can be seen that compared with the cell activity in the blank cell culture medium, with the increase of the concentration of exosome nanoparticles in Blank mEXO and Blank DPP-mEXO solutions, the cell activity did not decrease significantly, and the survival rate was above 80%. Therefore, it is proved that the exosome nanoparticles have less toxicity to biological cells.

[0131] (5) Mucus penetration experiment of drug-loaded nanoparticles

[0132] HT-29 cells were cultured in advance at a rate of 1 × 10 5 The cells were seeded at a density of 100 cells / well in a confocal dish and cultured for about two weeks. After they secreted enough mucus, they were used in the experiment. The dye used in the experiment was DIO (diluted at 1:1000) to label mEXO. 1 mL of mEXO@ins nanoparticles was prepared as in Example (1) and mixed with DSPE-PEG 2k -PEP co-incubation was performed while adding 50 μL of diluted DIO solution and incubating at 37°C in a shaker in the dark for 4 h. After the incubation, the solution was transferred to a 15 kDa dialysis bag and dialyzed with high-purity water for 2 h to finally obtain the exosome solution labeled with DIO.

[0133] During the experiment, the HT-29 cell culture medium was discarded, and the cells were washed three times with 200 μL sterilized PBS solution at pH 7.4 and 100 mM, and 100 μL of DPP-mEXO@ins nanoparticles prepared by the above process were added, and incubated at 37°C for 4 h. After incubation, the cells were washed three times with PBS, and 200 μL of Alexa 555-WGA (diluted 1:1000) was added and incubated for 10 min to stain the mucus. After staining, the cells were washed three times with PBS, and a drop of anti-fluorescence quencher was added, and the confocal dish was wrapped with tin foil and stored in a refrigerator at 4°C. During observation, three-dimensional images were taken with a confocal scanning microscope, and the data were reconstructed in 3D using ZEN software.

[0134] Nanoparticle mucus penetration Figure 8As shown, the green fluorescence is nanoparticles, and the red fluorescence is the mucus layer. It can be seen that the green fluorescence intensity of mEXO and DPP-mEXO is concentrated on the lower side of the mucus layer, indicating that both mEXO and DPP-mEXO have passed through the HT-29 cell layer, showing enhanced mucus permeability.

[0135] (6) In vivo hypoglycemic experiment

[0136] Drug-loaded polymer micelles and drug-loaded nanoparticles were orally administered to mice with type 1 diabetes induced by streptozotocin (STZ) to evaluate their in vivo performance in treating hyperglycemia. The hyperglycemic model mice were randomly divided into two groups, with 3 mice in each group. The mice were fasted the night before the experiment and had free access to water. The mEXO@ins and DPP-mEXO@ins solutions prepared in steps (1) and (2) of Example 2 were orally administered (administered at an insulin dose of 25U / kg) for in vivo experiments. Blood samples (~3μL) were collected through the tail vein, and blood glucose changes were continuously monitored and recorded every hour using a blood glucose meter. The mice were fed for 20 minutes at the 1st, 5th, and 10th hours to simulate the environment of three meals a day, and they were kept fasting at other times.

[0137] Blood sugar change curve is attached Fig. 9 As shown, Fig. 9 This is a graph of exosome-loaded nanoparticles lowering blood sugar levels in vivo. Fig. 9 It can be seen that the drug-loaded nanoparticles all showed a certain hypoglycemic effect, and after the mice briefly ate, the blood sugar level rose briefly and then quickly dropped to normal levels. The blood sugar of mice treated with DPP-mEXO@ins nanoparticles dropped to normal levels faster, and the drug effect lasted longer than that of the mEXO@ins group, proving that DSPE-PEG 2k -PEP material's more efficient transmembrane effect and liver targeting effect can enable hypoglycemic drugs to enter the body faster and exert a long-lasting hypoglycemic effect.

Claims

1. A drug carrier for liver-targeted exosome delivery, characterized in that: The drug carrier is a liver-targeting ligand DSPE-PEG-Pep, and its structural formula is as follows: Where n represents the average number of polyethylene glycols.

2. A method for preparing a drug carrier for liver-targeted exosome delivery according to claim 1, characterized in that: The method is: Maleimide-polyethylene glycol-distearoylphosphatidylethanolamine DSPE-PEG-MAL was modified with the liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys by Michael addition to obtain the liver-targeted ligand DSPE-PEG-Pep.

3. The method for preparing a drug carrier for liver-targeted exosome delivery according to claim 2, characterized in that: The method specifically comprises: dissolving DSPE-PEG-MAL and liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys with an organic solvent under a nitrogen protection environment, adding a catalyst, stirring the reaction at room temperature, and collecting the product after the reaction is completed, which is the liver-targeted ligand DSPE-PEG-Pep.

4. The method for preparing a drug carrier for liver-targeted exosome delivery according to claim 3, characterized in that: The organic solvent is DMF, methanol or chloroform; And / or, the catalyst is triethylamine; And / or, the molar ratio of DSPE-PEG-MAL to the liver-targeted pH-triggered stretchable cell-penetrating peptide Pep-cys is 1-1.5:

1.

5. A liver-targeted exosome nanoparticle, characterized in that: The liver-targeted exosome nanoparticles include the liver-targeted ligand DSPE-PEG-Pep described in claim 1, exosomes and insulin; wherein the exosomes are loaded with insulin in a self-assembled manner and then co-incubated with the liver-targeted ligand to obtain the liver-targeted exosome nanoparticles.

6. The liver-targeted exosome nanoparticles according to claim 5, characterized in that: The source of the exosomes includes any one of milk exosomes, ginger exosomes and cell exosomes.

7. A method for preparing liver-targeted exosome nanoparticles, characterized in that: The following steps are involved: The insulin solution was mixed with the exosome solution, and then ultrasonically treated. The drug-loaded nanoparticles obtained by fully mixing and assembling were recorded as mEXO@ins. The DSPE-PEGPep solution was mixed with mEXO@ins for co-incubation. After the incubation, the unconnected ligand structure was removed by centrifugation, and the obtained liver-targeted drug-loaded nanoparticles were DSPE-PEG-Pep-mEXO@ins.

8. The method for preparing liver-targeted exosome nanoparticles according to claim 7, characterized in that: The method for extracting exosomes is as follows: firstly, the macromolecular substances and precipitates in the material are removed, then the supernatant is centrifuged to remove the vesicles and small molecular substances, and finally, the exosomes are precipitated using a high-speed centrifuge tube and an ultra-high-speed refrigerated centrifuge.

9. The method for preparing liver-targeted exosome nanoparticles according to claim 7, characterized in that: The ultrasonic program of the ultrasonic treatment is 75-120W, 2-5min; and / or, when the DSPE-PEG-Pep solution is mixed with mEXO@ins, the volume ratio is 1:5-10; And / or, the centrifugal condition is 2000-3500r·min -1 , 3-5min.

10. Use of the drug carrier for liver-targeted exosome delivery according to claim 1 or the liver-targeted exosome nanoparticles according to claim 5 or 6 in the preparation of a drug for treating diabetes.